Author | Assis, Tália Santana Machado de | |
Author | Freire, Mariana Lourenço | |
Author | Carvalho, Janaína de Pina | |
Author | Rabello, Ana Lúcia Teles | |
Author | Cota, Gláucia Fernandes | |
Access date | 2022-12-19T12:43:41Z | |
Available date | 2022-12-19T12:43:41Z | |
Document date | 2022 | |
Citation | ASSIS, Tália Santana Machado de et al. Cost-effectiveness of anti-SARS-CoV-2 antibody diagnostic tests in Brazil. PLoS One, v. 17, n. 2, e0264159, 2022. doi: 10.1371/journal.pone.0264159. | en_US |
ISSN | 1932-6203 | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/56045 | |
Language | eng | en_US |
Publisher | Public Library of Science | en_US |
Rights | open access | en_US |
Title | Cost-effectiveness of anti-SARS-CoV-2 antibody diagnostic tests in Brazil | en_US |
Type | Article | en_US |
Abstract | Background: Although serologic tests for COVID-19 diagnosis are rarely indicated nowadays, they remain commercially available and widely used in Brazil. The objective of this study was to evaluate the cost-effectiveness of anti-SARS-CoV-2antibody diagnostic tests for COVID-19 in Brazil.
Methods: Eleven commercially available diagnostic tests, comprising five lateral-flow immunochromatographic assays (LFAs) and six immunoenzymatic assays (ELISA) were analyzed from the perspective of the Brazilian Unified Health System.
Results: The direct costs of LFAs ranged from US$ 11.42 to US$ 17.41and of ELISAs, from US$ 6.59 to US$ 10.31. Considering an estimated disease prevalence between 5% and 10%, the anti-SARS-CoV-2 ELISA (IgG) was the most cost-effective test, followed by the rapid One Step COVID-19 Test, at an incremental cost-effectiveness ratio of US$ 2.52 and US$ 1.26 per properly diagnosed case, respectively. Considering only the LFAs, at the same prevalence estimates, two tests, the COVID-19 IgG/IgM and the One Step COVID-19 Test, showed high effectiveness at similar costs. For situations where the estimated probability of disease is 50%, the LFAs are more costly and less effective alternatives.
Conclusions: Nowadays there are few indications for the use of serologic tests in the diagnosis of COVID-19 and numerous commercially available tests, with marked differences are observed among them. In general, LFA tests are more cost-effective for estimated low-COVID-19-prevalences, while ELISAs are more cost-effective for high-pretest-probability scenarios | en_US |
Affilliation | Centro Federal de Educação Tecnológica de Minas Gerais. Contagem, MG, Brazil/Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecto-Parasitárias. Belo Horizonte, MG, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecto-Parasitárias. Belo Horizonte, MG, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecto-Parasitárias. Belo Horizonte, MG, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecto-Parasitárias. Belo Horizonte, MG, Brazil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecto-Parasitárias. Belo Horizonte, MG, Brazil. | en_US |